Oct 20, 2021

New Duke University-led Study Shows That Vaxart’s Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model

Posted by in category: biotech/medical

SOUTH SAN FRANCISCO, Calif., Oct. 7 2021 /PRNewswire/ — A Duke University-led study published in bioRxiv showed that Vaxart, Inc.’s (NASDAQ: VXRT) investigational oral tablet vaccine reduced the airborne transmission of SARS-CoV-2 virus in an animal model.

These results are consistent with those from Vaxart’s Phase II human flu challenge study, which showed that Vaxart’s oral tablet vaccine was better at reducing shedding than the injectable flu vaccine comparator.

A limitation of the currently approved injected COVID-19 vaccines is that airborne transmission occurs in people who have received them. The preclinical study also demonstrated that Vaxart’s oral vaccine platform induces robust systemic and mucosal responses.

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Leave a reply